CVI Accepts, published online ahead of print on 30 September 2009
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Perry, A. L.
Right arrow Articles by Parker, A. R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Perry, A. L.
Right arrow Articles by Parker, A. R.

 Previous Article  |  Next Article 

Clin. Vaccine Immunol. doi:10.1128/CVI.00294-09
Copyright (c) 2009, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Comparison of five commercial anti-tetanus toxoid IgG ELISAs: Diagnostic and clinical interpretations.

A. L. Perry, A. J. Hayes, H. A. Cox, F. Alcock, and A. R. Parker*

Binding Site Limited, PO Box 11712, Birmingham, B14 4ZB, United Kingdom

* To whom correspondence should be addressed. Email: antony.parker{at}bindingsite.co.uk.


arrow
Abstract

Five commercially available enzyme-linked immunosorbant assays (ELISAs) for the measurement of anti-tetanus toxoid IgG antibodies were evaluated for performance. The data suggests that there are manufacturer dependent differences in sensitivity and accuracy for the determination of tetanus toxoid IgG antibodies that could result in different diagnostic interpretations.






Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»